Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Revance Reports Fourth Quarter and Full Year 2023 Financial Results
Revance to Participate in Upcoming Investor Conferences
Revance to Release Fourth Quarter and Full Year 2023 Financial Results
Revance Receives Permanent J-Code for DAXXIFY®
Revance Provides Preliminary Fourth Quarter and Full Year 2023 Financial Results
A Tennessee federal judge on Wednesday declined to dismiss a trade secrets lawsuit against Revance Therapeutics, which launched a Botox rival in 2022 and is currently working on a biosimilar.
Analysts Just Slashed Their Revance Therapeutics, Inc. (NASDAQ:RVNC) EPS Numbers
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update